| | 625115-55-1 Basic information More.. |
| Product Name: | Riociguat | | Synonyms: | Riociguat;N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methylcarbamic acid methyl ester;Bay 63-2521;Carbamic acid, (4,6-diamino-2-(1-((2-fluorophenyl)methyl)-1H-pyrazolo(3,4-B)pyridin-3-yl)-5-pyrimidinyl)methyl-, methyl ester;Riociguat (BAY 63-2521);Bay63-2521,Riociguat;[4,6-DiaMino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidin-5-yl]MethylcarbaMic acid Methyl ester;Methyl (4,6-diaMino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyriMidin-5-yl)(Methyl)carbaMate | | CAS: | 625115-55-1 | | MF: | C20H19FN8O2 | | MW: | 422.42 | | EINECS: | 641-755-1 | | Mol File: | 625115-55-1.mol |  |
Use
In September 2013, Health Canada approved riociguat (also referred to as BAY 63-2521), for the treatment of patients with chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH and for the treatment of adults with pulmonary arterial hypertension (PAH). A carbamate ester that is the methyl ester of {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamic acid. It is used for treatment of chronic thromboembolic pulmonary hypertension an pulmonary arterial hypertension
- Riociguat
-
- US $0.00-0.00 / g
- 2025-07-04
- CAS:625115-55-1
- Min. Order: 1g
- Purity: 98.0%
- Supply Ability: 10kg/month
- Riociguat
-
- US $0.00-0.00 / g
- 2025-07-03
- CAS:625115-55-1
- Min. Order: 10g
- Purity: 99%
- Supply Ability: 10 kg
- Riociguat
-
- US $0.00 / kg
- 2025-07-02
- CAS:625115-55-1
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 100kgs
|
|
625115-55-1
Recommend Suppliers |
|